Item 8.01 Other Events

As previously disclosed in a definitive proxy statement dated July 1, 2022, Health Sciences Acquisitions Corporation 2, a Cayman Islands exempted company ("HSAC2" or the "Company"), will hold an extraordinary general meeting of shareholders (the "General Meeting") on July 26, 2022 for the purposes of considering and voting upon a special resolution (the "Extension Proposal") to amend the Company's amended and restated memorandum and articles of association (together, the "Existing Charter") to: (i) extend from August 6, 2022 (the "Original Termination Date') to November 6, 2022 (the "Extended Date"), the date by which, if the Company has not consummated a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganisation or similar business combination involving one or more businesses or entities, the Company must liquidate and dissolve, and (ii) allow the Company, without another shareholder vote, to elect to extend the date to consummate a business combination on a monthly basis for up to three times by an additional one month each time after the Extended Date, upon five days' advance notice prior to the applicable deadlines, until February 6, 2023 or a total of up to six months after the Original Termination Date, unless the closing of the Company's initial business combination shall have occurred. HSAC2 shareholders are not being asked to vote on a business combination at the General Meeting.

The submission of the Extension Proposal to amend HSAC2's Existing Charter entitled holders of public shares to redeem their shares for their pro rata portion of the funds held in the trust account established at the time of the HSAC2 initial public offering. In connection with the General Meeting, as of July 22, 2022, HSAC2 has received requests for redemption from shareholders with respect to 9,237,883 HSAC2 ordinary shares.

On July 22, 2022, certain investment funds (the "RTW Funds") managed by RTW Investments, LP, an affiliate of the sponsor of HSAC2, purchased 1,000,000 HSAC2 ordinary shares at a price of $10.01 per share from an accredited investor ("Seller") in a privately negotiated transaction. The RTW Funds purchased such shares in order to (i) fulfill their obligations under the Forward Purchase Agreement, dated as of July 4, 2022, by and among HSAC2, Orchestra BioMed, Inc. ("Orchestra") and the RTW Funds, entered into in connection with the proposed business combination between HSAC2 and Orchestra (the "Business Combination"), and (ii) ensure that such shares purchased were not redeemed and the amounts that would have been paid by HSAC2 to Seller if such shares were redeemed remain in the Company's trust account at the closing of the Business Combination. This purchase increases the likelihood that the Business Combination ultimately closes.





                                       1

© Edgar Online, source Glimpses